Itrack Global Data Registry To Support The Role Of Canaloplasty For Treatment Of Glaucoma
Published 2023 - 41st Congress of the ESCRS
Reference: PO0845 | Type: Free paper | DOI: 10.82333/cfjj-yg72
Authors: David Lubeck* 1 , Keith Barton 2 , Nathan Kerr 3 , Iqbal Ike Ahmed 4
1Arbor Centers for EyeCare,Homewood, Illinois,United States, 2Moorfields Eye Hospital,London,United Kingdom, 3Centre for Eye Research Australia,East Melbourne, Victoria,Australia, 4Alan S Crandall Center for Glaucoma Innovation,University of Utah School of Medicine,Salt Lake City, Utah,United States
Purpose
The iTrack Global Data Registry (iTGDR) aims to collate efficacy and safety data for canaloplasty including: IOP reduction, number of medications, endothelial cell count, adverse events and complications, in addition to canaloplasty-specific treatment parameters.
Setting
Cloud based International Glaucoma Surgery Registry (IGSR).
Methods
Prospective multicenter cloud-based database, real-world study including patients with primary and secondary open angle glaucoma undergoing canaloplasty. The iTGDR is a surgeon-led initiative conducted in collaboration with the International Glaucoma Surgery Registry (IGSR). It collects longitudinal data of efficacy (IOP, number of medications, RNFL analysis, HVF), and safety (endothelial cell loss, adverse events and complications). The iTGDR started in January 2022 in the USA, Canada, Europe, Asia and Australia. The outcomes will be followed for at least 12 months. A minimum of 300 patients will be enrolled.
Results
313 eyes have been enrolled up to March 2023. 70.3% were primary open angle glaucoma (OAG) and 96.8% were phakic. Glaucoma stage was early (63.3%), moderate (20.6%), severe (8.7%) and advanced (7.3%). Ab-interno canaloplasty was performed in 100% of the eyes. Mean baseline IOP and medications were 18.42±6.13 and 2.07±1.20. Mean 12-month IOP and medications (n=39) were reduced to 13.44±4.37 and 0.95±1.23. Combined phaco-canaloplasty was done in 87.5%. 360o catheterization was achieved in 88.2% of the eyes. The most common OVD type used was Healon Pro (53.0%). Microhyphema (≤10% of the anterior chamber) occurred in 30 eyes (9%) and hyphema (>10% of the anterior chamber) in 7 eyes (2%). No eye needed further glaucoma surgery.
Conclusions
The iTGDR will make a major contribution to understanding the clinical effectiveness of canaloplasty to guide evidence-based decision making for surgeons to achieve improved outcomes in the treatment of their glaucoma patients.